Bioventix PLC
LSE:BVXP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 170
5 060
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bioventix PLC
Bioventix PLC
Cash from Financing Activities
Bioventix PLC
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioventix PLC
LSE:BVXP
|
Cash from Financing Activities
-£7.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash from Financing Activities
$21.1m
|
CAGR 3-Years
149%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash from Financing Activities
-$883k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash from Financing Activities
$519.9m
|
CAGR 3-Years
58%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash from Financing Activities
£34.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash from Financing Activities
-£2.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioventix PLC
Glance View
Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.
See Also
What is Bioventix PLC's Cash from Financing Activities?
Cash from Financing Activities
-7.8m
GBP
Based on the financial report for Dec 31, 2023, Bioventix PLC's Cash from Financing Activities amounts to -7.8m GBP.
What is Bioventix PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-6%
Over the last year, the Cash from Financing Activities growth was 2%. The average annual Cash from Financing Activities growth rates for Bioventix PLC have been -7% over the past three years , -6% over the past five years .
You don't have any saved screeners yet
